These findings indicate that IL-1β antagonism might be a therapeutic option in diabetic and non-diabetic CKD and emphasize the relevance of our present results showing an inhibitory effect of Empa on IL-1β-mediated gene expression in HPTCs. Here, IL1B is linked to chronic kidney disease.